Dr. Postow Discusses Side Effects with Combinations in Melanoma

Michael A. Postow, MD
Published: Monday, Mar 05, 2018



Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses side effects with combination therapy in melanoma.

Side effects with combination therapies in melanoma remain a big issue, says Postow. The management of patients’ side effects while on therapy for melanoma is very important, whether it is with combination therapy or monotherapy.

One of the most powerful immunotherapy combinations, ipilimumab (Yervoy) plus nivolumab (Opdiv), does have many side effects despite its efficacy in treating melanoma. Postow says that they are currently trying to tweak that regimen to make it more tolerable for patients, while maintaining its efficacy.


Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses side effects with combination therapy in melanoma.

Side effects with combination therapies in melanoma remain a big issue, says Postow. The management of patients’ side effects while on therapy for melanoma is very important, whether it is with combination therapy or monotherapy.

One of the most powerful immunotherapy combinations, ipilimumab (Yervoy) plus nivolumab (Opdiv), does have many side effects despite its efficacy in treating melanoma. Postow says that they are currently trying to tweak that regimen to make it more tolerable for patients, while maintaining its efficacy.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Evolving Roles for Targeted Melanoma Therapies: Assessing Rapid Progress in the Field and Looking Toward Future CombinationsFeb 28, 20191.5
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Publication Bottom Border
Border Publication
x